List of Excipients in Branded Drug ADVILL LIQUI-GELS

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mechanical Servants LLC	ADVILL LIQUI-GELS	ibuprofen capsule, liquid-filled	29485-2893	FD&C GREEN NO. 3
Mechanical Servants LLC	ADVILL LIQUI-GELS	ibuprofen capsule, liquid-filled	29485-2893	GELATIN
Mechanical Servants LLC	ADVILL LIQUI-GELS	ibuprofen capsule, liquid-filled	29485-2893	LECITHIN, SOYBEAN

Advil Liqui-Gels Excipient Strategy and Commercial Opportunities

Last updated: October 19, 2026

Advil Liqui-Gels is a 200 mg ibuprofen liquid-filled hard gelatin capsule sold as an over-the-counter analgesic and antipyretic. Its commercial differentiation comes from rapid disintegration, recognizable capsule presentation, dosing convenience, and brand trust rather than a novel active ingredient. The principal excipient opportunity is to improve dissolution consistency, shell performance, stability, swallowability, and sustainability without increasing manufacturing cost or triggering avoidable regulatory complexity.

What is the formulation of Advil Liqui-Gels?

Advil Liqui-Gels contains ibuprofen as the active ingredient at 200 mg per capsule. The liquid fill is enclosed in a gelatin shell and uses excipients that support solubilization, dispersion, pH control, capsule manufacture, printability, and stability.

Public product labeling identifies the following inactive ingredients for Advil Liqui-Gels:

Formulation component	Publicly identified role
Gelatin	Capsule shell-forming polymer
Polyethylene glycol	Liquid vehicle and solubilization aid
Potassium hydroxide	pH adjustment and ibuprofen salt formation or neutralization control
Purified water	Processing solvent
Sorbitol-sorbitan solution	Plasticizer and shell flexibility aid
Lecithin	Wetting, dispersion, and interfacial stabilization
Mineral oil	Processing or formulation aid
Pharmaceutical ink	Capsule printing
Colorants, where applicable	Brand identification and visual differentiation

The exact quantitative composition, fill volume, manufacturing process parameters, particle-size distribution, and shell specifications are proprietary. The FDA labeling framework confirms the product’s composition at the ingredient-class level but does not disclose a complete commercial manufacturing formula.[1]

Why is ibuprofen difficult to formulate?

Ibuprofen is a weak acid with limited water solubility in its neutral form. Its dissolution can vary with particle size, pH, wetting, fill viscosity, capsule-shell behavior, and gastrointestinal conditions. A liquid-filled capsule can improve dispersion and dissolution relative to a conventional compressed tablet, but only if the fill maintains physical and chemical stability throughout shelf life.

The formulation must also manage:

• Ibuprofen sedimentation or crystallization.
• Interaction between the fill and gelatin shell.
• Shell brittleness at low humidity.
• Shell softening or deformation at high humidity.
• Migration of water or plasticizer.
• Fill leakage and seal integrity.
• Oxidation or degradation of excipients.
• Manufacturing variability at high production volumes.

The product is therefore an excipient-and-process system rather than a simple ibuprofen solution.

What excipient strategy does Advil Liqui-Gels use?

The formulation strategy has four principal elements.

Liquid-fill delivery

The liquid fill is intended to disperse or solubilize ibuprofen rapidly after the capsule shell ruptures. Polyethylene glycol provides a compatible vehicle with useful viscosity and solvent properties. Potassium hydroxide can increase the apparent solubility of ibuprofen by controlling the fill’s alkalinity and promoting formation of a more soluble ibuprofen salt fraction.

The commercial tradeoff is that higher pH may improve dissolution but can increase compatibility risks with gelatin and affect long-term stability. The formulation must balance dissolution performance against shell integrity and chemical robustness.

Gelatin shell engineering

Gelatin provides a mature, low-cost capsule technology with established equipment and supply chains. Sorbitol-sorbitan solution functions as a plasticizing system, helping the shell remain flexible during manufacturing, packaging, transport, and use.

Shell formulation is commercially important because the capsule is the consumer-facing delivery system. Changes in gelatin bloom strength, plasticizer level, moisture content, color, or shell thickness can affect:

• Disintegration time.
• Mechanical strength.
• Leakage risk.
• Appearance.
• Printing quality.
• Consumer swallowing experience.

A replacement shell based on hydroxypropyl starch, pullulan, or hydroxypropyl methylcellulose could support vegetarian or religious-diet positioning, but would require reformulation, stability work, process validation, and new consumer testing.

Interfacial control

Lecithin can support wetting and dispersion of ibuprofen in the liquid vehicle. Mineral oil may contribute to processing behavior or formulation performance, although its precise function in the commercial product is not disclosed in the public label.

Interfacial stability is a key development target for follow-on products. A formulation that initially appears homogeneous but later develops sediment, phase separation, or crystallization would create both quality and consumer-perception problems.

Brand-color and identification system

Colorants and pharmaceutical ink create product recognition and support counterfeit detection. For a branded OTC product, capsule appearance has commercial value. A substitute product that matches the pharmacotechnical performance but lacks visual recognition may have difficulty commanding a premium.

What formulations are protected by patents or regulatory exclusivity?

Advil Liqui-Gels is based on ibuprofen, an established active ingredient that is widely available as a generic OTC medicine. Its regulatory position is primarily governed by the FDA OTC monograph framework rather than a new-drug exclusivity period.

Ibuprofen is permitted for OTC analgesic and antipyretic use under the FDA’s applicable monograph requirements, including dosage, labeling, and safety conditions.[2] The product does not depend on biologic exclusivity, biosimilar rules, or a new molecular entity exclusivity period.

Regulatory issue	Advil Liqui-Gels position
Active ingredient	Ibuprofen
Strength	200 mg per capsule
FDA pathway	OTC monograph framework
New chemical entity exclusivity	Not applicable
Biosimilar pathway	Not applicable
Orange Book dependence	Generally not the principal competitive mechanism
Paragraph IV exposure	Not central to ordinary OTC monograph competition
Primary barriers	Brand, formulation know-how, manufacturing, quality, packaging, and distribution

Publicly available product information does not establish a current, product-defining patent that would prevent ordinary manufacture of an ibuprofen liquid-filled capsule. A competitor could still pursue patents covering a specific vehicle, shell composition, release profile, manufacturing process, or stability improvement. Such patents would need to claim a non-obvious technical distinction rather than the broad concept of an ibuprofen softgel.

When does Advil Liqui-Gels lose exclusivity?

Advil Liqui-Gels does not have a single conventional patent-expiration date that determines generic entry. The active ingredient is long established, and OTC competitors can market ibuprofen products under the applicable FDA monograph if they satisfy the regulatory requirements.

Commercial exclusivity persists through brand equity, shelf placement, advertising, package design, retailer relationships, and perceived performance. This is different from statutory exclusivity.

The competitive timeline is therefore:

Period	Competitive condition
Historical launch period	Brand established differentiation through liquid-filled capsule delivery
Current market	Generic and store-brand ibuprofen products compete broadly
Post-formulation improvement	A new delivery or shell technology could create limited patent or trade-secret protection
Long-term	Brand remains exposed to private-label substitution and retailer price competition

Are there Paragraph IV challenges or Orange Book listings?

Paragraph IV litigation is generally associated with abbreviated new drug applications challenging listed patents for an approved prescription product. Advil Liqui-Gels competes primarily in the OTC monograph market, where the standard Paragraph IV pathway is not the central mechanism for market entry.

The product’s competitive exposure is instead driven by:

• Monograph-compliant generic ibuprofen capsules.
• Store-brand liquid-filled ibuprofen products.
• Conventional ibuprofen tablets and caplets.
• Ibuprofen suspensions and chewable products.
• Acetaminophen products.
• Combination analgesics.

No product-specific Orange Book patent position is established by the public labeling sources cited here. A company evaluating an entry strategy should not assume that an Orange Book listing blocks OTC competition.

How strong is the patent estate for Advil Liqui-Gels?

The publicly visible patent position appears weaker than the commercial position. The product benefits from manufacturing know-how and brand assets that may not be fully disclosed in patent documents.

Potentially protectable technical features

A follow-on or reformulated product could seek protection for:

1. A high-solubility ibuprofen liquid fill.
2. A reduced-crystallization vehicle.
3. A gelatin or non-gelatin shell with improved moisture control.
4. A rapid-disintegration capsule.
5. A lower-viscosity fill that improves manufacturing throughput.
6. A formulation with reduced shell migration.
7. A taste-masked or lower-odor capsule.
8. A sustainable shell or renewable excipient system.
9. A capsule optimized for pediatric or geriatric swallowing.
10. A dual-release or gastroprotective delivery system.

Broad claims to ibuprofen in a gelatin capsule would face substantial validity and freedom-to-operate pressure because softgel ibuprofen products are established. Narrow claims tied to measured dissolution, excipient ratios, stability results, or manufacturing parameters would have better prospects if supported by comparative data.

What commercial opportunities exist for new excipients?

Vegetarian and clean-label capsules

A non-gelatin shell could target consumers who avoid animal-derived ingredients. Hydroxypropyl methylcellulose and other plant-derived systems are commercially established, but they may require optimization for oxygen permeability, moisture transfer, sealing, and rupture behavior.

The opportunity is strongest in premium OTC, e-commerce, specialty retail, and markets with high demand for vegetarian products. The risk is cost. A plant-based shell can increase raw-material and conversion expense without improving analgesic efficacy.

Faster dissolution

A new vehicle using optimized co-solvents, surfactants, or micronized ibuprofen could seek faster dissolution than conventional liquid-filled capsules. The commercial claim must be linked to validated in vitro performance and compliant labeling. Faster dissolution does not automatically establish faster clinical pain relief.

A technically credible product would need comparative data covering:

• Initial dissolution rate.
• Total drug release.
• Physical stability.
• Capsule disintegration.
• Long-term crystallization.
• Bioavailability, if a pharmacokinetic claim is pursued.

Lower environmental impact

Excipient and packaging changes could reduce environmental burden through:

• Plant-derived shell polymers.
• Lower-plastic blister systems.
• Recyclable bottles.
• Reduced solvent use.
• Lower-energy drying.
• More concentrated packaging configurations.

Sustainability claims require documented lifecycle and packaging evidence. They are unlikely to support a premium price unless connected to credible certification and visible package differentiation.

Pediatric and geriatric delivery

Liquid-filled capsules are not ideal for consumers who cannot swallow capsules. A chewable, mini-softgel, orally disintegrating, or suspension-based ibuprofen product could expand use among pediatric and older populations.

The main development issues include taste masking, dose flexibility, accidental overuse, choking risk, and age-appropriate labeling. A smaller capsule with the same 200 mg dose may improve swallowing for some adults but would not solve pediatric dosing requirements.

Combination products

Ibuprofen-acetaminophen combinations could create a higher-value product category, but they introduce formulation and labeling complexity. The two actives have different physicochemical properties and dosing considerations. A liquid-filled capsule could use a dual-phase or multiparticulate design, but stability and dose-uniformity requirements would be demanding.

How does Advil Liqui-Gels compare with competing ibuprofen products?

Product category	Main advantage	Main weakness	Excipient opportunity
Advil Liqui-Gels	Brand, liquid-filled presentation, convenience	Premium price and brand substitution	Faster dissolution, shell sustainability
Generic ibuprofen softgels	Low price	Lower brand recognition	Retailer-specific appearance and stability
Ibuprofen tablets	Lowest cost and simple logistics	Slower disintegration for some formulations	Direct-compression and fast-disintegrating systems
Ibuprofen suspensions	Flexible dosing	Taste, dosing errors, bulky packaging	Taste masking and improved suspension stability
Acetaminophen products	Different analgesic profile	Liver-toxicity labeling concerns at excess doses	Combination or differentiated delivery
Ibuprofen caplets	Familiar, durable dosage form	Less premium consumer experience	Film coating, swallowability, and dose convenience

The strongest commercial threat is private-label liquid-filled ibuprofen, not a biosimilar or prescription generic entrant. The strongest opportunity is a differentiated delivery system that earns a measurable consumer benefit while preserving OTC monograph compliance.

What manufacturing and intellectual-property barriers matter?

The main barriers are operational rather than molecule-level patent barriers.

A commercial manufacturer must control:

• Ibuprofen particle size and purity.
• Fill homogeneity.
• Capsule seam integrity.
• Gelatin moisture content.
• Temperature and humidity during encapsulation.
• In-process weight variation.
• Dissolution and disintegration.
• Stability under accelerated and long-term conditions.
• Packaging moisture protection.
• Printing and serialization controls.

Trade secrets can protect fill preparation, temperature profiles, deaeration, encapsulation parameters, shell drying, and inspection methods. These controls may be more valuable than broad formulation patents because they directly affect yield and defect rates.

Excipient suppliers also create commercial dependencies. A change in gelatin source, polyethylene glycol grade, lecithin quality, plasticizer composition, or ink system may require supplier qualification and comparability work.

What is the litigation and licensing outlook?

Public sources cited here do not identify a major current patent dispute, Paragraph IV campaign, or settlement agreement controlling Advil Liqui-Gels market access. The product’s main legal exposure is more likely to arise from:

• Trademark and trade-dress disputes.
• Advertising claims.
• Product liability.
• Labeling and dosage errors.
• Manufacturing-quality investigations.
• Antitrust or retail-pricing issues.
• Patent disputes involving a specific reformulation.

Licensing opportunities are more plausible for excipient technology, capsule shells, sustainable packaging, or specialized fill systems than for the ibuprofen active ingredient. A technology owner could license a shell or vehicle platform to OTC manufacturers seeking premium differentiation without developing a new active ingredient.

What revenue exposure does the product create?

Haleon, which owns the Advil consumer-health brand, reports results at broader category and brand-group levels rather than disclosing standalone Advil Liqui-Gels revenue in the public materials cited here.[3] Product-level revenue therefore cannot be isolated from public company reporting.

Commercial exposure depends on:

• Advil brand pricing.
• Liquid-filled capsule share within Advil.
• U.S. retailer distribution.
• Private-label price gaps.
• Seasonal pain and fever demand.
• Promotional intensity.
• Consumer switching to acetaminophen or generic ibuprofen.
• Manufacturing continuity.

The product is strategically valuable even without standalone revenue disclosure because it supports a premium dosage-form architecture within a high-volume OTC category.

Key Takeaways

• Advil Liqui-Gels uses a 200 mg ibuprofen liquid-filled gelatin capsule.
• The formulation relies on polyethylene glycol, potassium hydroxide, gelatin, sorbitol-sorbitan solution, lecithin, purified water, and other capsule-processing ingredients.
• Its primary commercial protection is brand strength and manufacturing know-how, not a publicly established active-ingredient patent monopoly.
• OTC monograph competition reduces the importance of Paragraph IV litigation and conventional Orange Book exclusivity.
• The strongest excipient opportunities are faster dissolution, non-gelatin shells, improved stability, pediatric or geriatric delivery, and lower-impact packaging.
• A follow-on patent position would need narrow, data-supported claims covering a specific formulation or manufacturing result.
• Private-label softgels are the principal competitive threat.
• Product-level revenue is not separately disclosed by Haleon in the cited public reporting.

FAQs About Advil Liqui-Gels Excipient Strategy

What is the main solvent in Advil Liqui-Gels?

Public labeling identifies polyethylene glycol as a key inactive ingredient. The precise grade, concentration, and role within the liquid fill are proprietary.

Does Advil Liqui-Gels contain gelatin?

Yes. The capsule shell uses gelatin, with sorbitol-sorbitan solution identified among the inactive ingredients.

Can a competitor make a generic ibuprofen liquid gel?

Yes, provided the product satisfies applicable FDA OTC requirements, quality standards, labeling rules, and any valid rights covering a specific formulation, process, trademark, or trade dress.

Is Advil Liqui-Gels protected by a biosimilar patent strategy?

No. Biosimilar rules apply to biological products, not to ibuprofen, which is a small-molecule drug.

What is the most valuable reformulation opportunity?

A formulation that combines rapid and consistent dissolution with a stable, lower-cost, non-gelatin or lower-moisture shell has the clearest commercial potential. It would need comparative performance data and a credible consumer benefit.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Advil Liqui-Gels ibuprofen capsule, liquid filled labeling. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use.
3. Haleon plc. (2024). Annual report and financial statements 2023. London, United Kingdom: Haleon plc.